Abstract 241P
Background
Human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC) is well known to have a relatively indolent behavior, and it should be staged separately. P16 is a useful surrogate marker for HPV status in OP region. However, the low prevalence of HPV infection in Taiwan (lower than 30%) may cause increased possibility of false positive for p16 staining. This study is aimed to determine the concordance of p16 IHC stain and HPV RNA ISH in Taiwan population.
Methods
There were 141 oropharyngeal cancer patients are retrieved from the archives of VGHTC from 2016 to 2020. HE stain was done and reviewed by 2 pathologist and p16 IHC stain was performed for all cases. Forty-nine (34.8%) of all cases were p16(+) oropharyngeal cancer. HPV-ISH was done for p16(+) oropharyngeal cancer patients.
Results
HPV-ISH found 44 (89.7%) of 49 cases were HPV-ISH (+). On univariate analysis, p16 (+) oropharyngeal cancer patients had better 3-year overall survival (90.4 % vs. 73.4 %, p=0.02) and 3-year disease-free survival (95.4% vs. 65.3%, p=0.0005) than p16(-) oropharyngeal cancer patients. HPV-ISH (+) oropharyngeal cancer patients also had better 3-year overall survival (92.0 % vs. 73.5 %, p=0.02) and 3-year disease-free survival (94.9% vs. 67.4%, p=0.002) than HPV-ISH(-) oropharyngeal cancer patients. We also found p16(+)HPVISH(+) oropharngeal cancer patients had better 3-year disease-free survival than p16(-)HPVISH(-) oropharngeal cancer patients (94.9% vs. 65.3%, p=0.002).
Conclusions
By far, p16 is still a useful surrogate marker for OPSCC in Taiwan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract